AI in Drug Discovery Market by Process (Target, Lead), Use Case (Repurposing, DE Novo Drug Design [Vaccine] Optimization, Disease Understanding, PK/PD), Therapy (Cancer, CNS), Tool (DL [CNN, GAN]), End User - Global Forecast to 2031

Market Size
$5.09B
MARKET SIZE, 2026
Projected Market Size
$17.56B
MARKET SIZE, 2031
CAGR
28.1%
CAGR (2026-2031)
Forecast Period
2026-2031
FORECAST PERIOD

AI IN DRUG DISCOVERY MARKET SIZE, SHARE & GROWTH SNAPSHOT

ai-in-drug-discovery-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global AI in drug discovery market is projected to grow from USD 5.09 billion in 2026 to USD 17.56 billion by 2031, at a CAGR of 28.1% during the forecast period. The market was valued at USD 3.92 billion in 2025. The market is driven by growing pharmaceutical demand to reduce drug discovery timelines and R&D costs, increasing adoption of generative AI and foundation models, expanding availability of multi-omics datasets, and investments in AI-enabled drug discovery platforms. Increasing strategic collaborations between pharmaceutical companies and AI technology providers, coupled with advances in cloud computing, high-performance computing, and computational biology, are further boosting the adoption of AI across early-stage drug discovery.

KEY TAKEAWAYS

  • MARKET SNAPSHOT:
    Base Year Market Size (2025): USD 3.92 Billion
    Current Market Size (2026): USD 5.09 Billion
    Forecast Market Size (2031): USD 17.56 Billion
    CAGR (2026–2031): 28.1%
  • SEGMENT LEADERSHIP:
    Regional Leader: North America accounted for a 44.9% share of the AI in drug discovery market in 2025.
    Process Leader: Hit-to-lead identification/lead generation segment is expected to register the highest CAGR between 2026 and 2031.
    Use Case Leader: De novo drug design segment is projected to grow at the fastest rate from 2026 to 2031.
    Therapeutic Area Leader: Oncology segment held the largest share of 38.6% in 2025.
    Player Type Leader: AI technology providers segment is projected to grow at the fastest rate from 2026 to 2031.
    AI Tool Leader: Machine learning segment is expected to dominate the market during the forecast period.
    Deployment Model Leader: Cloud-based model is projected to exhibit a CAGR of 28.7% during the forecast period.
    End User Leader: Pharmaceutical & biotechnology companies segment accounted for the largest share in the AI in drug discovery market in 2025.
  • MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
    NVIDIA Corporation, Schrodinger, Inc., and Recursion were identified as some of the star players in the AI in drug discovery market, given their strong market share and product footprint.
    Xaira Therapeutics, Inc., Converge Bio, and CellType Inc., among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.

The AI in drug discovery market is undergoing a fundamental shift from hypothesis-driven research to data-driven drug discovery, enabling researchers to identify novel biological targets, predict molecular interactions, and prioritize high-potential drug candidates with greater confidence. AI is enabling pharmaceutical companies to integrate diverse datasets spanning genomics, proteomics, transcriptomics, scientific literature, and real-world evidence, improving decision-making throughout the discovery pipeline. As AI models become increasingly predictive and scalable, organizations are adopting AI as a core component of early-stage drug discovery to enhance portfolio quality, increase research productivity, and improve the probability of successful therapeutic development.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The AI in drug discovery market is evolving from fragmented, stage-specific applications toward integrated discovery ecosystems that connect biological data, computational chemistry, and experimental validation within a unified workflow. Pharmaceutical companies are increasingly adopting AI platforms to improve decision-making across the discovery pipeline, enabling faster prioritization of drug candidates and more informed portfolio management. This transition from isolated AI tools to enterprise-scale discovery platforms is reshaping technology investments and positioning AI as a strategic capability for next-generation pharmaceutical innovation.

ai-in-drug-discovery-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Rising need to reduce time and cost of drug discovery and development
  • Growing utilization of AI to predict drug-target interactions for cancer therapy
RESTRAINTS
Impact
Level
  • Shortage of AI workforce and regulatory frameworks for AI-enabled drug discovery
  • Increasing AI compute infrastructure costs amid global HBM/DRAM/NAND shortage
OPPORTUNITIES
Impact
Level
  • Accelerating biotech drug discovery
  • AI-driven single-cell analysis for biomarker and disease-subtype identification
CHALLENGES
Impact
Level
  • Limited availability of high-quality training datasets
  • Limited real-world clinical validation of AI-derived drug candidates

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Rising need to reduce time and cost of drug discovery and development

The rising need to reduce the time and cost associated with drug discovery and development is a major factor driving the adoption of AI in drug discovery. Developing a new medicine remains a lengthy, resource-intensive process, with high attrition rates across the development pipeline. According to PhRMA, bringing a new medicine to market takes an average of 10–15 years and costs approximately USD 2.6 billion, including the cost of failed drug candidates, while only 12% of new molecular entities entering clinical trials ultimately receive FDA approval. These challenges have accelerated the adoption of AI to improve target identification, optimize lead compounds, and prioritize promising drug candidates with greater speed and accuracy. By reducing reliance on iterative laboratory experimentation and improving decision-making during early-stage research, AI enables pharmaceutical companies to enhance R&D productivity, shorten discovery timelines, and improve the probability of successful drug development.

Restraint: Shortage of AI workforce and regulatory frameworks for AI-enabled drug discovery

The shortage of professionals with expertise spanning artificial intelligence, computational biology, medicinal chemistry, and drug discovery remains a significant challenge for the widespread adoption of AI in pharmaceutical R&D. Successful implementation of AI platforms requires multidisciplinary teams capable of developing, validating, and interpreting complex AI models while integrating them into existing drug discovery workflows. At the same time, regulatory frameworks governing the use of AI-generated evidence in drug discovery continue to evolve, creating uncertainty around model validation, transparency, reproducibility, and regulatory acceptance. According to the World Economic Forum's Future of Jobs Report 2025, the demand for AI and big data specialists is expected to grow by over 80% by 2030, making them among the fastest-growing job categories globally. However, the limited availability of professionals with combined expertise in AI and life sciences, coupled with evolving regulatory expectations from agencies such as the US FDA and EMA regarding AI-enabled drug development, may slow technology adoption and increase implementation complexity for pharmaceutical companies.

Opportunity: Accelerating biotech drug discovery

The expanding adoption of AI across biotechnology companies presents a significant growth opportunity for the AI in drug discovery market. Unlike large pharmaceutical companies, many biotechnology firms are AI-native or are rapidly integrating AI to accelerate target identification, de novo drug design, biomarker discovery, and lead optimization while operating with leaner R&D budgets. According to the Biotechnology Innovation Organization (BIO), emerging biotechnology companies account for approximately 70% of the global drug development pipeline, highlighting their growing role in pharmaceutical innovation. AI enables these companies to rapidly validate biological hypotheses, prioritize high-value drug candidates, and advance promising assets into preclinical development with greater efficiency. Increasing investments in AI-native biotechnology startups, expanding collaborations with pharmaceutical companies, and growing availability of cloud-based AI platforms are expected to further accelerate AI adoption across the biotechnology sector, creating substantial growth opportunities for AI technology providers during the forecast period.

Challenge: Limited availability of high-quality training datasets

The limited availability of high-quality, diverse, and well-annotated biological datasets remains a significant challenge for AI in drug discovery market. AI models require access to large volumes of validated genomic, proteomic, chemical, clinical, and real-world data to generate reliable predictions across target identification, molecular design, and lead optimization. However, much of this data remains fragmented across pharmaceutical companies, academic institutions, and public repositories, with varying formats, quality standards, and accessibility. Proprietary data ownership, privacy concerns, and intellectual property restrictions further limit data sharing and model development. According to the OECD's 2024 report, limited access to high-quality, interoperable scientific datasets is one of the primary barriers to developing robust AI models across scientific disciplines, including biomedical research. Addressing these data quality and interoperability challenges will be essential to improving the accuracy, reproducibility, and scalability of AI-enabled drug discovery solutions.

AI IN DRUG DISCOVERY MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
GPU-accelerated computing, BioNeMo foundation models, generative AI, molecular simulation, and high-performance computing platforms supporting target discovery, protein engineering, molecular design, and virtual screening Faster AI model training | Accelerated molecular discovery | Reduced computational time | Scalable drug discovery workflows | Improved research productivity
Physics-based molecular modeling, computational chemistry, AI-assisted drug design, virtual screening, and lead optimization through an integrated computational drug discovery platform Higher prediction accuracy | Improved lead optimization | Lower experimental costs | Accelerated candidate selection | Increased probability of clinical success
Generative AI-powered target identification, de novo molecule generation, biomarker discovery, and end-to-end drug discovery through the Pharma.AI platform integrating biology, chemistry, and clinical data Shortened discovery timelines | Rapid identification of novel drug candidates | Improved target validation | Enhanced R&D efficiency | Reduced drug development costs
AI-driven phenomics platform combining high-content cellular imaging, machine learning, automated experimentation, and large-scale biological datasets for target discovery and therapeutic development Faster target identification | Improved biological insights | Higher-quality candidate selection | Increased experimental throughput | Enhanced translational research efficiency
AI foundation models, protein structure prediction, cloud-based AI infrastructure, and multimodal data analytics supporting drug target discovery, molecular modeling, and biomedical research Improved biological understanding | Accelerated target discovery | Scalable AI infrastructure | Enhanced predictive modelling | Faster scientific innovation

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The AI in Drug Discovery market operates within a collaborative ecosystem comprising pharmaceutical companies, biotechnology firms, AI technology providers, contract research organizations (CROs), academic and research institutions, cloud service providers, and regulatory agencies. Increasing convergence of artificial intelligence, computational biology, high-performance computing, and multi-omics research is accelerating innovation across the drug discovery value chain. Strategic collaborations between AI platform developers and pharmaceutical companies are enabling the development of scalable, data-driven discovery platforms, while advances in cloud computing and laboratory automation are supporting the transition toward integrated and AI-native drug discovery workflows.

ai-in-drug-discovery-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

ai-in-drug-discovery-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

AI in Drug Discovery Market, By Process

Based on process, the hit-to-lead identification/lead generation segment accounted for the largest share of the AI in drug discovery market in 2025. The segment's dominance is driven by the increasing adoption of AI-powered virtual screening, molecular property prediction, and generative chemistry tools that enable rapid identification and optimization of promising lead compounds. By analyzing vast chemical libraries and integrating biological, structural, and pharmacological data, AI significantly improves the quality of lead candidates while reducing the need for resource-intensive laboratory screening. Recent advancements in machine learning and generative AI have further enhanced the efficiency of hit-to-lead workflows, enabling pharmaceutical and biotechnology companies to accelerate early-stage drug discovery, improve candidate success rates, and optimize R&D productivity.

AI in Drug Discovery Market, By Use Case

In 2025, the de novo drug design segment accounted for the largest share of the AI in drug discovery market. This dominance is driven by the increasing adoption of generative AI, deep learning, and computational chemistry platforms that enable the design of novel molecules with desired biological and physicochemical properties. AI-powered de novo drug design significantly accelerates the identification and optimization of potential drug candidates by exploring vast chemical spaces beyond conventional compound libraries. The growing integration of generative models with molecular simulation, structure-based drug design, and predictive analytics has further enhanced the efficiency and success of early-stage drug discovery. As pharmaceutical and biotechnology companies increasingly invest in AI-native drug discovery platforms, de novo drug design continues to play a pivotal role in accelerating innovation and improving R&D productivity.

AI in Drug Discovery Market, By Therapeutic Area

In 2025, the oncology segment accounted for the largest share of the AI in drug discovery market. This dominance is driven by the increasing global cancer burden, extensive oncology drug development pipelines, and the growing adoption of AI to accelerate the discovery of targeted therapies and immuno-oncology drugs. AI enables researchers to analyze complex genomic, transcriptomic, proteomic, and clinical datasets for biomarker identification, target discovery, patient stratification, and lead optimization. The availability of large-scale oncology datasets, coupled with substantial pharmaceutical investments in precision oncology, has further accelerated AI adoption across cancer research. As the demand for personalized cancer therapies continues to grow, oncology is expected to remain the leading therapeutic area in the AI in drug discovery market.

AI in Drug Discovery Market, By Player Type

By player type, the end-to-end solution providers segment accounted for the largest share of the AI in drug discovery market in 2025. The segment's leadership is driven by the growing demand for integrated AI platforms that support the entire drug discovery workflow, from target identification and hit discovery to lead optimization and candidate selection. Pharmaceutical and biotechnology companies increasingly prefer comprehensive solutions that combine artificial intelligence, computational chemistry, multi-omics data integration, molecular modeling, and predictive analytics within a unified platform. These end-to-end platforms improve workflow efficiency, reduce integration complexity, and enable seamless data exchange across discovery stages. As organizations continue to consolidate technology vendors and adopt enterprise-wide AI strategies, end-to-end solution providers are expected to maintain their leading position in the AI in drug discovery market.

AI in Drug Discovery Market, By AI Tool

By AI tool, the machine learning segment is expected to dominate the AI in drug discovery market, registering the highest CAGR during the forecast period. The segment is driven by the widespread application of machine learning algorithms across target identification, virtual screening, molecular property prediction, hit prioritization, and lead optimization. Machine learning enables rapid analysis of large-scale biological, chemical, and multi-omics datasets, improving the accuracy of predictive models while reducing reliance on time-intensive experimental approaches. Continuous advancements in deep learning, graph neural networks, and generative AI are further expanding the capabilities of machine learning in molecular design and drug candidate optimization. As pharmaceutical and biotechnology companies increasingly integrate AI into their discovery workflows, machine learning is expected to remain the fastest-growing AI tool in the AI in drug discovery market.

AI in Drug Discovery Market, By Deployment Model

By deployment model, the cloud-based deployment segment accounted for the largest share of the AI in drug discovery market in 2025. The segment's dominance is driven by the increasing demand for scalable computing infrastructure capable of supporting AI model training, molecular simulations, and the analysis of large-scale biological and chemical datasets. Cloud-based platforms enable pharmaceutical and biotechnology companies to securely store, process, and share research data while facilitating collaboration across geographically distributed R&D teams. In addition, cloud deployment provides flexible access to high-performance computing resources, reducing infrastructure costs and accelerating AI-driven drug discovery workflows. As organizations continue to adopt cloud-native research environments and integrate AI across the drug discovery pipeline, cloud-based deployment is expected to maintain its leading position in the market.

AI in Drug Discovery Market, By End User

By end user, the pharmaceutical & biotechnology companies segment accounted for the largest share of the AI in drug discovery market in 2025. The segment's dominance is driven by increasing investments in AI-enabled drug discovery platforms to accelerate target identification, lead optimization, and candidate selection while improving R&D productivity. Pharmaceutical and biotechnology companies are leveraging AI to analyze complex biological and chemical datasets, enhance predictive modeling, and reduce dependence on conventional trial-and-error approaches in early-stage drug discovery. The growing need to improve pipeline productivity, address rising R&D costs, and accelerate the development of novel therapeutics has further increased the adoption of AI across pharmaceutical research. As AI becomes an integral component of modern drug discovery strategies, pharmaceutical and biotechnology companies are expected to remain the largest end users of AI-driven drug discovery solutions.

REGION

Asia Pacific to be fastest-growing region in AI in drug discovery market

Asia Pacific is the fastest-growing AI in drug discovery market, supported by the rapid expansion of pharmaceutical and biotechnology research, increasing availability of genomic and clinical datasets, and growing investments in AI-native drug discovery companies. The region is emerging as a global hub for computational drug discovery, driven by expanding cloud infrastructure, high-performance computing capabilities, and a strong pipeline of AI-enabled biotechnology startups. China, Japan, South Korea, Singapore, and India are witnessing increasing adoption of AI across target identification, molecular design, and lead optimization, while collaborations between regional biotechnology companies and global pharmaceutical manufacturers continue to accelerate technology commercialization. These factors are positioning the region as a key growth engine for AI-enabled drug discovery during the forecast period.

ai-in-drug-discovery-market Region

AI IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX

NVIDIA Corporation (Star) holds a leading position in the AI in drug discovery market through its accelerated computing platforms, BioNeMo foundation models, and GPU-optimized AI ecosystem that power molecular simulation, predictive modeling, virtual screening, and generative drug design. Its strong collaborations with pharmaceutical companies, biotechnology firms, and research institutions, coupled with continued investments in high-performance computing and agentic AI, reinforce its leadership in enabling scalable AI-driven drug discovery. Microsoft Corporation (Emerging Leader) is rapidly strengthening its market presence through Azure AI, cloud-native infrastructure, and advanced AI development services that support large-scale biological data integration, AI model training, target identification, and collaborative drug discovery. The company's expanding partnerships across the pharmaceutical and life sciences ecosystem position it as a key enabler of next-generation AI-powered therapeutics and digital R&D transformation.

ai-in-drug-discovery-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2025 (Value) USD 3.92 Billion
Market Size in 2026 (Value) USD 5.09 Billion
Market Forecast in 2031 (Value) USD 17.56 Billion
CAGR 28.1%
Years Considered 2024–2031
Base Year 2025
Forecast Period 2026–2031
Units Considered Value (USD Billion)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered
  • By Process:
    • Target Identification & Selection
    • Target Validation
    • HIT Identification & Prioritisation
    • HIT-TO-LEAD Identification/Lead Generation
    • Lead Optimisation
    • and Candidate Selection & Validation
  • By Use Case:
    • Understanding Diseases
    • Drug Repurposing
    • De Novo Drug Design
    • Drug Optimisation
    • and Safety & Toxicity
  • By Therapeutic Area:
    • Oncology
    • Infectious Diseases
    • Neurology
    • Metabolic Diseases
    • Cardiovascular Diseases
    • Immunology
    • Mental Health Disorders
    • and Other Therapeutic Areas
  • By Player Type:
    • End-to-End Solution Providers
    • Niche/Point Solution Providers
    • Technology Providers
    • and Business Process Service Providers
  • By AI Tool:
    • Machine Learning
    • Natural Language Processing
    • Context-Aware Processing & Computing
    • and Computer Vision
    • Image Analysis
  • By Deployment Model:
    • On-premises
    • Cloud-based
    • Hybrid
  • By End User:
    • Pharmaceutical & Biotechnology Companies
    • Contract Research Organizations
    • Research Centers
    • Academic & Government Institutes
Regions Covered North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa

WHAT IS IN IT FOR YOU: AI IN DRUG DISCOVERY MARKET REPORT CONTENT GUIDE

ai-in-drug-discovery-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Map the AI in drug discovery ecosystem Comprehensive ecosystem mapping across pharmaceutical companies, biotechnology firms, AI technology providers, CROs, academic & research institutes, cloud providers, regulators, and data providers Provides clear visibility into the market ecosystem and value chain, enabling strategic partnership, investment, and ecosystem expansion decisions
Understand AI integration across the drug discovery value chain In-depth analysis of AI adoption across target identification, hit discovery, lead optimization, candidate selection, data integration, cloud deployment models, and computational biology platforms Reduces technology adoption risk and supports AI roadmap development aligned with pharmaceutical R&D priorities
Identify high-growth AI use cases across drug discovery Prioritized assessment of AI applications across disease understanding, drug repurposing, de novo drug design, drug optimization, and preclinical testing Enables focused product development, technology investments, and commercialization strategies in high-growth applications
Benchmark competitors in the AI in drug discovery landscape Competitive benchmarking of leading AI drug discovery companies Strengthens competitive positioning, identifies technology gaps, and uncovers whitespace opportunities for differentiation
Assess regulatory, data governance, and commercialization trends Analysis of evolving AI governance frameworks, data privacy requirements, intellectual property considerations, AI validation practices, and pharmaceutical regulatory trends influencing AI adoption Supports regulatory readiness, risk mitigation, and commercialization strategies while improving long-term market competitiveness

RECENT DEVELOPMENTS

  • July 2026 : Insilico Medicine and Takeda Pharmaceutical entered a strategic AI-driven drug discovery collaboration valued at up to USD 600 million to discover and develop novel therapeutics across multiple disease areas using Insilico's Pharma.AI platform.
  • June 2026 : Insilico Medicine and SK Biopharmaceuticals announced a strategic collaboration worth up to USD 2.5 billion to leverage AI for the discovery of novel therapies targeting neuroimmune disorders, combining Insilico's AI platform with SK Biopharmaceuticals' neuroscience expertise.
  • March 2026 : NVIDIA Corporation introduced next-generation BioNeMo foundation models and agentic AI capabilities at GTC 2026, enabling pharmaceutical and biotechnology companies to accelerate molecular design, protein engineering, target discovery, and AI-driven drug development workflows.

 

Table of Contents

checkmarkExclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
 
 
49
2
EXECUTIVE SUMMARY
 
 
 
 
 
57
3
PREMIUM INSIGHTS
 
 
 
 
 
64
4
MARKET OVERVIEW
AI-driven collaborations redefine drug discovery, slashing costs and accelerating innovation amidst patent expirations.
 
 
 
 
 
67
 
4.1
INTRODUCTION
 
 
 
 
 
 
4.2
MARKET DYNAMICS
 
 
 
 
 
 
 
4.2.1
DRIVERS
 
 
 
 
 
 
 
4.2.1.1
INCREASING NUMBER OF CROSS-INDUSTRY COLLABORATIONS AND PARTNERSHIPS
 
 
 
 
 
 
4.2.1.2
RISING NEED TO REDUCE TIME AND COST OF DRUG DISCOVERY AND DEVELOPMENT
 
 
 
 
 
 
4.2.1.3
PATENT EXPIRY OF DRUGS AND NEED FOR EFFECTIVE NEW LEADS
 
 
 
 
 
 
 
GROWING UTILIZATION OF AI TO PREDICT DRUG-TARGET INTERACTIONS FOR
 
 
 
 
 
 
4.2.1.5
INTEGRATION OF AI-ASSISTED MULTIOMICS IN DRUG DISCOVERY
 
 
 
 
 
 
 
GROWING FOCUS ON RARE DISEASE TREATMENTS FOR ORPHAN
 
 
 
 
 
4.2.2
RESTRAINTS
 
 
 
 
 
 
 
4.2.2.1
SHORTAGE OF AI WORKFORCE AND AMBIGUOUS REGULATORY GUIDELINES FOR MEDICAL SOFTWARE
 
 
 
 
 
4.2.3
OPPORTUNITIES
 
 
 
 
 
 
 
4.2.3.1
LEVERAGING AI FOR ACCELERATED BIOTECH DRUG DISCOVERY
 
 
 
 
 
 
4.2.3.2
INCREASED FOCUS ON DRUG DISCOVERY IN EMERGING ECONOMIES
 
 
 
 
 
 
4.2.3.3
FOCUS ON DEVELOPING HUMAN-AWARE AI SYSTEMS
 
 
 
 
 
 
4.2.3.4
GROWING USE OF AI IN SINGLE-CELL ANALYSIS
 
 
 
 
 
 
 
EASY IDENTIFICATION OF BIOMARKER AND DISEASE SUBTYPES FROM
 
 
 
 
 
 
4.2.3.6
HIGH DEMAND FOR PRECISION AND PERSONALIZED MEDICINES
 
 
 
 
 
4.2.4
CHALLENGES
 
 
 
 
 
 
 
4.2.4.1
LIMITED AVAILABILITY OF QUALITY DATA SETS
 
 
 
 
 
 
4.2.4.2
LACK OF ADVANCED AI TOOLS AND TRAINING DATA SETS
 
 
 
 
 
 
4.2.4.3
COMPUTATIONAL CONSTRAINTS OF ADVANCED AI MODELS
 
 
 
 
 
 
4.2.4.4
LACK OF HIGH-QUALITY DATA SETS FOR MODEL TRAINING
 
 
 
 
4.3
UNMET NEEDS AND WHITE SPACES
 
 
 
 
 
 
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
 
 
 
 
 
 
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
 
 
 
 
 
5
INDUSTRY TRENDS
AI-driven drug discovery reshapes competitive dynamics and pricing in the pharmaceutical industry.
 
 
 
 
 
84
 
5.1
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
 
5.1.1
BARGAINING POWER OF SUPPLIERS
 
 
 
 
 
 
5.1.2
BARGAINING POWER OF BUYERS
 
 
 
 
 
 
5.1.3
THREAT OF SUBSTITUTES
 
 
 
 
 
 
5.1.4
THREAT OF NEW ENTRANTS
 
 
 
 
 
 
5.1.5
INTENSITY OF COMPETITIVE RIVALRY
 
 
 
 
 
5.2
MACROECONOMIC INDICATORS
 
 
 
 
 
 
 
5.2.1
INTRODUCTION
 
 
 
 
 
 
5.2.2
GDP TRENDS AND FORECAST
 
 
 
 
 
 
5.2.3
GLOBAL PHARMACEUTICAL R&D EXPENDITURE AND PRODUCTIVITY TRENDS
 
 
 
 
 
5.3
VALUE CHAIN ANALYSIS
 
 
 
 
 
 
 
 
5.3.1
RESEARCH, DATA GENERATION, AND SCIENTIFIC INPUTS
 
 
 
 
 
 
5.3.2
DATA ENGINEERING & AI INFRASTRUCTURE
 
 
 
 
 
 
5.3.3
AI MODEL & PLATFORM DEVELOPMENT
 
 
 
 
 
 
5.3.4
AI WORKFLOW INTEGRATION & DEPLOYMENT
 
 
 
 
 
 
5.3.5
DRUG DISCOVERY SERVICES & EXPERIMENTAL EXECUTION
 
 
 
 
 
 
5.3.6
VALIDATION, LAB-IN-THE-LOOP, AND CONTINUOUS OPTIMIZATION
 
 
 
 
 
5.4
ECOSYSTEM ANALYSIS
 
 
 
 
 
 
 
5.5
PRICING ANALYSIS
 
 
 
 
 
 
 
 
5.5.1
INDICATIVE PRICE FOR AI IN DRUG DISCOVERY PLATFORMS, BY KEY PLAYERS (2025)
 
 
 
 
 
 
5.5.2
INDICATIVE PRICE FOR AI IN DRUG DISCOVERY SOFTWARE AND SERVICES, BY REGION (2025)
 
 
 
 
 
5.6
KEY CONFERENCES AND EVENTS, 2026–2027
 
 
 
 
 
 
5.7
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
 
 
 
 
 
 
5.8
INVESTMENT AND FUNDING SCENARIO
 
 
 
 
 
 
5.9
CASE STUDY ANALYSIS
 
 
 
 
 
 
5.10
IMPACT OF 2025 US TARIFF – AI IN DRUG DISCOVERY MARKET
 
 
 
 
 
 
 
 
5.10.1
INTRODUCTION
 
 
 
 
 
 
5.10.2
KEY TARIFF RATES
 
 
 
 
 
 
5.10.3
PRICE IMPACT ANALYSIS
 
 
 
 
 
 
5.10.4
IMPACT ON COUNTRY/REGION
 
 
 
 
 
 
 
5.10.4.1
US
 
 
 
 
 
 
5.10.4.2
EUROPE
 
 
 
 
 
 
5.10.4.3
ASIA-PACIFIC
 
 
 
 
 
5.10.5
IMPACT ON END-USE INDUSTRIES
 
 
 
 
 
 
 
5.10.5.1
PHARMACEUTICAL COMPANIES
 
 
 
 
 
 
5.10.5.2
BIOTECHNOLOGY COMPANIES
 
 
 
 
 
 
5.10.5.3
CROS AND CDMOS
 
 
 
 
 
 
5.10.5.4
ACADEMIC AND RESEARCH USERS
 
 
 
 
 
 
5.10.5.5
OTHER END USERS
 
 
 
 
STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL,
 
 
 
 
 
 
 
6.1
KEY EMERGING TECHNOLOGIES
 
 
 
 
 
 
 
6.1.1
GENERATIVE AND AGENTIC AI FOR DRUG DISCOVERY
 
 
 
 
 
 
6.1.2
MULTIMODAL AI AND FOUNDATION MODELS
 
 
 
 
 
 
6.1.3
AI-ENABLED AUTONOMOUS LABORATORIES
 
 
 
 
 
6.2
COMPLEMENTARY TECHNOLOGIES
 
 
 
 
 
 
 
6.2.1
CLOUD COMPUTING AND HIGH-PERFORMANCE COMPUTING
 
 
 
 
 
 
6.2.2
HIGH-THROUGHPUT SCREENING AND LABORATORY AUTOMATION
 
 
 
 
 
6.3
ADJACENT TECHNOLOGIES
 
 
 
 
 
 
 
6.3.1
MULTIOMICS AND SINGLE-CELL TECHNOLOGIES
 
 
 
 
 
 
6.3.2
DIGITAL TWINS AND IN-SILICO CLINICAL TECHNOLOGIES
 
 
 
 
 
6.4
TECHNOLOGY/PRODUCT ROADMAP
 
 
 
 
 
 
6.5
PATENT ANALYSIS
 
 
 
 
 
 
 
 
6.5.1
PATENT PUBLICATION TRENDS FOR AI IN DRUG DISCOVERY MARKET
 
 
 
 
 
 
6.5.2
INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
 
 
 
 
 
6.6
FUTURE APPLICATIONS
 
 
 
 
 
 
 
6.6.1
AUTONOMOUS END-TO-END DRUG DISCOVERY
 
 
 
 
 
 
6.6.2
AI-DRIVEN PRECISION DRUG DISCOVERY AND PATIENT-SPECIFIC THERAPEUTICS
 
 
 
 
 
 
6.6.3
AI-ENABLED DIGITAL AND VIRTUAL DRUG DEVELOPMENT
 
 
 
 
7
REGULATORY LANDSCAPE
Navigate complex global regulations with insights into regional frameworks and compliance standards.
 
 
 
 
 
114
 
7.1
REGIONAL REGULATIONS AND COMPLIANCE
 
 
 
 
 
 
 
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, & OTHER ORGANIZATIONS
 
 
 
 
 
 
7.1.2
REGULATORY FRAMEWORK
 
 
 
 
 
 
 
7.1.2.1
NORTH AMERICA
 
 
 
 
 
 
7.1.2.2
EUROPE
 
 
 
 
 
 
7.1.2.3
ASIA PACIFIC
 
 
 
 
 
 
7.1.2.4
LATIN AMERICA
 
 
 
 
 
 
7.1.2.5
MIDDLE EAST & AFRICA
 
 
 
 
 
7.1.3
INDUSTRY STANDARDS
 
 
 
 
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
Understand the complex buyer dynamics and unmet needs shaping market profitability in drug discovery.
 
 
 
 
 
129
 
8.1
INTRODUCTION
 
 
 
 
 
 
8.2
DECISION-MAKING PROCESS
 
 
 
 
 
 
8.3
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
 
 
 
 
 
 
 
8.3.1
KEY STAKEHOLDERS IN BUYING PROCESS
 
 
 
 
 
 
8.3.2
BUYING CRITERIA
 
 
 
 
 
8.4
ADOPTION BARRIERS & INTERNAL CHALLENGES
 
 
 
 
 
 
8.5
UNMET NEEDS FROM VARIOUS END USERS
 
 
 
 
 
 
 
8.5.1
UNMET NEEDS
 
 
 
 
 
 
8.5.2
END USER EXPECTATIONS
 
 
 
 
 
8.6
MARKET PROFITABILITY
 
 
 
 
 
9
AI IN DRUG DISCOVERY MARKET, BY PROCESS
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 7 Data Tables
 
 
 
 
 
136
 
9.1
INTRODUCTION
 
 
 
 
 
 
9.2
TARGET IDENTIFICATION & SELECTION
 
 
 
 
 
 
 
9.2.1
INCREASED DEMAND FOR PERSONALIZED MEDICINES AND HIGH INVESTMENT IN PHARMACEUTICAL R&D TO FUEL MARKET GROWTH
 
 
 
 
 
9.3
TARGET VALIDATION
 
 
 
 
 
 
 
9.3.1
RISING EMPHASIS ON AVOIDING LATE-STAGE FAILURE IN DRUG DISCOVERY TO BOOST MARKET GROWTH
 
 
 
 
 
9.4
HIT IDENTIFICATION & PRIORITIZATION
 
 
 
 
 
 
 
9.4.1
NEED FOR LARGE-SCALE DATA ANALYSIS TO DRIVE ADOPTION
 
 
 
 
 
9.5
HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION
 
 
 
 
 
 
 
9.5.1
HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION TO IMPROVE NEW DRUG POTENCY WITHOUT INCREASING LIPOPHILICITY
 
 
 
 
 
9.6
LEAD OPTIMIZATION
 
 
 
 
 
 
 
 
NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS TO BOOST
 
 
 
 
 
9.7
CANDIDATE SELECTION & VALIDATION
 
 
 
 
 
 
 
9.7.1
HIGH POSSIBILITY OF CLINICAL DRUG FAILURE TO SPUR ADOPTION OF CANDIDATE VALIDATION SERVICES
 
 
 
 
10
AI IN DRUG DISCOVERY MARKET, BY AI TOOL
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 36 Data Tables
 
 
 
 
 
146
 
10.1
INTRODUCTION
 
 
 
 
 
 
10.2
MACHINE LEARNING
 
 
 
 
 
 
 
10.2.1
INCREASING AVAILABILITY OF COMPLEX BIOLOGICAL AND CHEMICAL DATASETS DRIVES ADOPTION
 
 
 
 
 
 
10.2.2
DEEP LEARNING
 
 
 
 
 
 
 
10.2.2.1
ABILITY TO CAPTURE COMPLEX NONLINEAR RELATIONSHIPS ACROSS MULTIMODAL BIOLOGICAL AND MOLECULAR DATA – KEY DRIVER
 
 
 
 
 
 
10.2.2.2
TRANSFORMER-BASED ARCHITECTURES
 
 
 
 
 
 
 
 
10.2.2.2.1
GROWING VOLUMES OF SEQUENTIAL, MULTIMODAL, AND UNSTRUCTURED SCIENTIFIC DATA DRIVES MARKET
 
 
 
 
10.2.2.3
GRAPH NEURAL NETWORKS (GNN)
 
 
 
 
 
 
 
 
10.2.2.3.1
NEED TO UNDERSTAND MOLECULAR STRUCTURE AND COMPLEX BIOLOGICAL RELATIONSHIPS SUPPORTS GNN ADOPTION
 
 
 
 
10.2.2.4
CONVOLUTIONAL NEURAL NETWORKS (CNN)
 
 
 
 
 
 
 
 
10.2.2.4.1
EXPANSION OF IMAGE-BASED AND 3D STRUCTURAL ANALYSIS BOOSTS ADOPTION
 
 
 
 
10.2.2.5
DIFFUSION AND FLOW-BASED MODELS
 
 
 
 
 
 
 
 
10.2.2.5.1
INCREASING DEMAND FOR CONTROLLED GENERATION OF NOVEL MOLECULES AND PROTEINS ACCELERATES SEGMENT GROWTH
 
 
 
 
10.2.2.6
GENERATIVE ADVERSARIAL NETWORKS (GAN) & VARIATIONAL AUTOENCODERS (VAE)
 
 
 
 
 
 
 
 
10.2.2.6.1
GROWING DEMAND FOR COMPUTATIONAL EXPLORATION OF CHEMICAL SPACE SUPPORTS GROWTH
 
 
 
 
10.2.2.7
RECURRENT & SEQUENCE MODELS (RNN, LSTM)
 
 
 
 
 
 
 
 
10.2.2.7.1
CONTINUED NEED TO MODEL SEQUENTIAL CHEMICAL AND BIOLOGICAL INFORMATION SUSTAINS DEMAND
 
 
 
 
10.2.2.8
OTHER DEEP LEARNING TECHNOLOGIES
 
 
 
 
 
 
 
 
10.2.2.8.1
EMERGENCE OF SPECIALIZED NEURAL ARCHITECTURES EXPANDS APPLICATIONS ACROSS COMPLEX DISCOVERY WORKFLOWS
 
 
 
10.2.3
SUPERVISED LEARNING
 
 
 
 
 
 
 
10.2.3.1
GROWING AVAILABILITY OF EXPERIMENTALLY VALIDATED DATASETS SUPPORTS SEGMENT
 
 
 
 
 
10.2.4
SELF-SUPERVISED & REPRESENTATION LEARNING
 
 
 
 
 
 
 
10.2.4.1
SHORTAGE OF LABELED BIOLOGICAL DATA AND GROWING AVAILABILITY OF UNLABELED DATASETS DRIVE ADOPTION
 
 
 
 
 
10.2.5
REINFORCEMENT LEARNING
 
 
 
 
 
 
 
10.2.5.1
NEED TO OPTIMIZE MOLECULES AND EXPERIMENTAL DECISIONS ACROSS MULTIPLE OBJECTIVES DRIVES ADOPTION
 
 
 
 
 
10.2.6
UNSUPERVISED LEARNING
 
 
 
 
 
 
 
10.2.6.1
INCREASING COMPLEXITY OF BIOLOGICAL DATASETS TO BOOST SEGMENT
 
 
 
 
 
10.2.7
OTHER MACHINE LEARNING TECHNOLOGIES
 
 
 
 
 
 
 
10.2.7.1
NEED TO EXTRACT VALUE FROM PARTIALLY LABELED AND HETEROGENEOUS DATASETS SUPPORTS SEGMENT
 
 
 
 
10.3
GENERATIVE AI
 
 
 
 
 
 
 
10.3.1
ABILITY TO DESIGN NOVEL MOLECULES AND BIOLOGICAL STRUCTURES ACCELERATES ADOPTION
 
 
 
 
 
 
10.3.2
MOLECULAR GENERATIVE MODELS
 
 
 
 
 
 
 
10.3.2.1
NEED TO EXPLORE LARGER CHEMICAL SPACES AND SIMULTANEOUSLY OPTIMIZE MULTIPLE MOLECULAR PROPERTIES – SEGMENT DRIVER
 
 
 
 
 
10.3.3
PROTEIN & BIOLOGICS GENERATIVE MODELS
 
 
 
 
 
 
 
10.3.3.1
GROWING DEMAND FOR ENGINEERED PROTEINS, ANTIBODIES, AND OTHER BIOLOGICS EXPANDS APPLICATIONS
 
 
 
 
 
10.3.4
LARGE LANGUAGE MODELS (LLMS)
 
 
 
 
 
 
 
10.3.4.1
RAPID GROWTH OF SCIENTIFIC LITERATURE AND UNSTRUCTURED RESEARCH DATA INCREASES DEMAND
 
 
 
 
10.4
FOUNDATION MODELS
 
 
 
 
 
 
 
10.4.1
NEED FOR REUSABLE AI MODELS TO LEARN FROM LARGE-SCALE, MULTIMODAL BIOLOGICAL DATASETS DRIVES ADOPTION
 
 
 
 
 
 
10.4.2
CHEMISTRY FOUNDATION MODELS
 
 
 
 
 
 
 
10.4.2.1
INCREASING NEED FOR REUSABLE MOLECULAR REPRESENTATION AND SCALABLE CHEMICAL INTELLIGENCE DRIVES SEGMENT
 
 
 
 
 
10.4.3
PROTEIN LANGUAGE MODELS
 
 
 
 
 
 
 
10.4.3.1
GROWING DEMAND FOR PROTEIN ENGINEERING AND FUNCTIONAL PREDICTION ACCELERATES ADOPTION
 
 
 
 
 
10.4.4
BIOLOGY AND MULTIOMICS FOUNDATION MODELS
 
 
 
 
 
 
 
10.4.4.1
INCREASING INTEGRATION OF GENOMIC, TRANSCRIPTOMIC, PROTEOMIC, AND CELLULAR DATA – KEY DRIVER
 
 
 
 
10.5
AGENTIC AI & AI CO-SCIENTISTS
 
 
 
 
 
 
 
10.5.1
GROWTH DRIVEN BY DEMAND FOR AUTONOMOUS RESEARCH WORKFLOWS AND IMPROVED SCIENTIST PRODUCTIVITY
 
 
 
 
 
 
10.5.2
AUTONOMOUS RESEARCH AGENTS & WORKFLOW ORCHESTRATION
 
 
 
 
 
 
 
10.5.2.1
NEED TO AUTOMATE COMPLEX MULTI-STEP RESEARCH PROCESSES DRIVES ADOPTION
 
 
 
 
 
10.5.3
MULTI-AGENT REASONING SYSTEMS
 
 
 
 
 
 
 
10.5.3.1
INCREASING COMPLEXITY OF SCIENTIFIC PROBLEMS CREATES DEMAND
 
 
 
 
 
10.5.4
LAB-IN-THE-LOOP & CLOSED-LOOP EXPERIMENTATION
 
 
 
 
 
 
 
10.5.4.1
INTEGRATION OF AI WITH AUTOMATED LABORATORIES ENABLES CONTINUOUS DESIGN–BUILD–TEST–LEARN WORKFLOWS
 
 
 
 
10.6
KNOWLEDGE GRAPHS AND SEMANTIC REASONING
 
 
 
 
 
 
 
10.6.1
NEED TO CONNECT FRAGMENTED SCIENTIFIC INFORMATION AND IDENTIFY HIDDEN RELATIONSHIPS DRIVES SEGMENT
 
 
 
 
 
10.7
NATURAL LANGUAGE PROCESSING (NLP)
 
 
 
 
 
 
 
10.7.1
EXPLOSION OF SCIENTIFIC LITERATURE, PATENTS, AND UNSTRUCTURED R&D INFORMATION DRIVES NLP ADOPTION
 
 
 
 
 
10.8
COMPUTER VISION & IMAGE ANALYSIS
 
 
 
 
 
 
 
10.8.1
INCREASING USE OF HIGH-CONTENT SCREENING, MICROSCOPY, AND PHENOTYPIC ASSAYS EXPANDS APPLICATIONS
 
 
 
 
 
10.9
PHYSICS-BASED & HYBRID AI METHODS
 
 
 
 
 
 
 
10.9.1
NEED FOR MECHANISTIC UNDERSTANDING AND IMPROVED ACCURACY IN MOLECULAR MODELING DRIVES SEGMENT
 
 
 
 
11
AI IN DRUG DISCOVERY MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 7 Data Tables
 
 
 
 
 
182
 
11.1
INTRODUCTION
 
 
 
 
 
 
11.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
 
 
 
 
 
 
 
11.2.1
GROWING PRESSURE TO ACCELERATE R&D PRODUCTIVITY AND REDUCE DRUG DISCOVERY COSTS DRIVES SEGMENT
 
 
 
 
 
 
11.2.2
LARGE PHARMACEUTICAL COMPANIES
 
 
 
 
 
 
 
11.2.2.1
HIGH R&D EXPENDITURE AND INCREASING NEED TO IMPROVE PIPELINE PRODUCTIVITY ACCELERATE AI ADOPTION
 
 
 
 
 
11.2.3
SMALL & MID-SIZED BIOTECHNOLOGY COMPANIES
 
 
 
 
 
 
 
11.2.3.1
LIMITED INTERNAL RESOURCES AND NEED FOR DIFFERENTIATED PIPELINES INCREASE RELIANCE ON AI-ENABLED DISCOVERY
 
 
 
 
11.3
CONTRACT RESEARCH ORGANIZATIONS (CROS) & CDMOS
 
 
 
 
 
 
 
11.3.1
INCREASING OUTSOURCING OF DRUG DISCOVERY ACTIVITIES DRIVES GROWTH
 
 
 
 
 
11.4
RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS
 
 
 
 
 
 
 
11.4.1
GROWING AVAILABILITY OF RESEARCH FUNDING AND ADVANCED AI CAPABILITIES EXPANDS GROWTH
 
 
 
 
12
AI IN DRUG DISCOVERY MARKET, BY USE CASE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 20 Data Tables
 
 
 
 
 
190
 
12.1
INTRODUCTION
 
 
 
 
 
 
12.2
UNDERSTANDING DISEASE BIOLOGY
 
 
 
 
 
 
 
12.2.1
INCREASED FOCUS ON UNDERSTANDING DISEASES TO IMPROVE RESEARCH DATA QUALITY AND QUANTITY
 
 
 
 
 
 
12.2.2
EVIDENCE SYNTHESIS AND SCIENTIFIC LITERATURE INTELLIGENCE
 
 
 
 
 
 
 
12.2.2.1
RAPID DATA ANALYSIS – KEY DEMAND DRIVER
 
 
 
 
 
12.2.3
MULTIOMICS INTEGRATION & TARGET-DISEASE ASSOCIATION
 
 
 
 
 
 
 
12.2.3.1
GROWING INTEGRATION OF GENOMIC, TRANSCRIPTOMIC, PROTEOMIC, METABOLOMIC, AND OTHER BIOLOGICAL DATASETS TO DRIVE MARKET
 
 
 
 
 
12.2.4
EXPERIMENT DESIGN & REAGENT/MODEL SELECTION
 
 
 
 
 
 
 
12.2.4.1
GROWING COMPLEXITY OF DISEASE BIOLOGY AND EXPERIMENT DESIGN BOOSTS DEMAND
 
 
 
 
12.3
PROTEIN STRUCTURE & INTERACTION PREDICTION
 
 
 
 
 
 
 
12.3.1
ADVANCES IN AI-POWERED PROTEIN INTERACTION PREDICTION ACCELERATE STRUCTURE-BASED DRUG DISCOVERY
 
 
 
 
 
12.4
DRUG REPURPOSING
 
 
 
 
 
 
 
12.4.1
INCREASING ADOPTION OF AI PLATFORMS FOR SYSTEMATIC DRUG REPURPOSING
 
 
 
 
 
12.5
DE NOVO DRUG DESIGN
 
 
 
 
 
 
 
12.5.1
SMALL MOLECULE DESIGN
 
 
 
 
 
 
 
 
INCREASING USE OF VIRTUAL SCREENING AND SIMULATION TECHNIQUES TO
 
 
 
 
 
12.5.2
VACCINE DESIGN
 
 
 
 
 
 
 
12.5.2.1
AVAILABILITY OF WELL-VALIDATED AI TOOLS TO BOOST MARKET GROWTH
 
 
 
 
 
12.5.3
ANTIBODY & OTHER BIOLOGICS DESIGN
 
 
 
 
 
 
 
12.5.3.1
ADVANCEMENTS IN PROTEIN MODELING TO PROPEL SEGMENT GROWTH
 
 
 
 
 
12.5.4
PROTEIN & ENZYME DESIGN
 
 
 
 
 
 
 
12.5.4.1
PROTEIN DESIGNING TO PROPEL SEGMENT GROWTH
 
 
 
 
12.6
DRUG OPTIMIZATION
 
 
 
 
 
 
 
12.6.1
SMALL MOLECULE OPTIMIZATION
 
 
 
 
 
 
 
12.6.1.1
GENERATIVE MODELS FOR POTENTIAL MODIFICATIONS IN MOLECULAR STRUCTURES TO AID MARKET GROWTH
 
 
 
 
 
12.6.2
VACCINE OPTIMIZATION
 
 
 
 
 
 
 
12.6.2.1
EFFECTIVE PREDICTION OF VACCINE FORMULATIONS AND ADJUSTMENT OF DELIVERY VECTORS TO DRIVE GROWTH
 
 
 
 
 
12.6.3
ANTIBODY & OTHER BIOLOGICS OPTIMIZATION
 
 
 
 
 
 
 
12.6.3.1
INCREASING ADOPTION OF MACHINE LEARNING TO PREDICT PROTEIN STRUCTURES TO AUGMENT SEGMENT GROWTH
 
 
 
 
12.7
SAFETY & TOXICITY
 
 
 
 
 
 
 
12.7.1
FOCUS ON ADVANCED OFF-TARGET EFFECT PREDICTION, PK/PD SIMULATION, AND QSP MODELING TO DRIVE MARKET
 
 
 
 
13
AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 7 Data Tables
 
 
 
 
 
211
 
13.1
INTRODUCTION
 
 
 
 
 
 
13.2
ON-PREMISE SOLUTIONS
 
 
 
 
 
 
 
13.2.1
GROWING DEMAND FOR DATA SOVEREIGNTY, IP PROTECTION, AND CONTROL OVER PROPRIETARY R&D DATA SUPPORTS GROWTH DEPLOYMENT
 
 
 
 
 
13.3
CLOUD-BASED SOLUTIONS
 
 
 
 
 
 
 
13.3.1
NEED FOR SCALABLE COMPUTING, RAPID AI DEPLOYMENT, AND COST-EFFICIENT ACCESS TO ADVANCED INFRASTRUCTURE - KEY DRIVERS
 
 
 
 
 
 
13.3.2
PUBLIC CLOUD
 
 
 
 
 
 
 
13.3.2.1
ELASTIC COMPUTING CAPACITY AND ACCESS TO ADVANCED AI INFRASTRUCTURE DRIVE ADOPTION
 
 
 
 
 
13.3.3
PRIVATE CLOUD/VPC/SOVEREIGN DEPLOYMENT
 
 
 
 
 
 
 
13.3.3.1
INCREASING DATA-SECURITY, IP-PROTECTION, AND DATA-RESIDENCY REQUIREMENTS STRENGTHEN DEMAND
 
 
 
 
13.4
HYBRID SOLUTIONS
 
 
 
 
 
 
 
13.4.1
NEED TO BALANCE COMPUTATIONAL SCALABILITY WITH CONTROL OVER SENSITIVE R&D DATA ACCELERATES ADOPTION
 
 
 
 
14
AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 10 Data Tables
 
 
 
 
 
218
 
14.1
INTRODUCTION
 
 
 
 
 
 
14.2
ONCOLOGY
 
 
 
 
 
 
 
14.2.1
HIGH PREVALENCE OF ONCOLOGY AND SHORTAGE OF EFFECTIVE ONCOLOGY DRUGS TO DRIVE MARKET GROWTH
 
 
 
 
 
14.3
INFECTIOUS DISEASES
 
 
 
 
 
 
 
14.3.1
RISING ANTIMICROBIAL RESISTANCE AND NEED FOR NOVEL ANTI-INFECTIVE THERAPIES TO DRIVE GROWTH
 
 
 
 
 
14.4
NEUROLOGY
 
 
 
 
 
 
 
14.4.1
HIGH DISEASE COMPLEXITY AND LIMITED TREATMENT OPTIONS DRIVE DEMAND FOR AI-ENABLED DISCOVERY
 
 
 
 
 
14.5
CARDIOVASCULAR DISEASES
 
 
 
 
 
 
 
14.5.1
GROWING CARDIOVASCULAR DISEASE BURDEN AND NEED FOR NOVEL THERAPEUTIC TARGETS BOOST GROWTH
 
 
 
 
 
14.6
METABOLIC DISEASES
 
 
 
 
 
 
 
14.6.1
RISING PREVALENCE OF OBESITY AND METABOLIC DISORDERS ACCELERATES DEMAND FOR INNOVATIVE THERAPIES
 
 
 
 
 
14.7
IMMUNOLOGY
 
 
 
 
 
 
 
14.7.1
COMPLEX IMMUNE MECHANISMS AND GROWING DEMAND FOR TARGETED THERAPIES DRIVE AI ADOPTION
 
 
 
 
 
14.8
RARE & GENETIC DISORDERS
 
 
 
 
 
 
 
 
LIMITED TREATMENT OPTIONS AND FRAGMENTED DISEASE DATA DRIVE
 
 
 
 
 
14.9
MENTAL HEALTH DISORDERS
 
 
 
 
 
 
 
14.9.1
HIGH UNMET NEED AND LIMITED UNDERSTANDING OF DISEASE MECHANISMS DRIVE SEGMENT GROWTH
 
 
 
 
 
14.10
OTHER THERAPEUTIC AREAS
 
 
 
 
 
 
 
14.10.1
EXPANDING APPLICATION OF AI ACROSS UNDEREXPLORED DISEASE AREAS DRIVES MARKET GROWTH
 
 
 
 
15
AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 6 Data Tables
 
 
 
 
 
230
 
15.1
INTRODUCTION
 
 
 
 
 
 
15.2
END-TO-END SOLUTION PROVIDERS
 
 
 
 
 
 
 
15.2.1
INCREASING ADOPTION OF INTEGRATED AI PLATFORMS ACROSS DRUG DISCOVERY WORKFLOW DRIVES GROWTH
 
 
 
 
 
15.3
NICHE/POINT SOLUTION PROVIDERS
 
 
 
 
 
 
 
15.3.1
GROWING DEMAND FOR SPECIALIZED AI CAPABILITIES TARGETING COMPLEX DISCOVERY CHALLENGES TO DRIVE GROWTH
 
 
 
 
 
15.4
AI TECHNOLOGY PROVIDERS
 
 
 
 
 
 
 
15.4.1
RAPID ADVANCES IN GENERATIVE AI, FOUNDATION MODELS, AND AGENTIC AI ACCELERATE DEMAND
 
 
 
 
 
15.5
COMPUTE & INFRASTRUCTURE PROVIDERS
 
 
 
 
 
 
 
15.5.1
GROWING COMPUTATIONAL REQUIREMENTS OF ADVANCED AI MODELS DRIVE DEMAND
 
 
 
 
 
15.6
BUSINESS PROCESS SERVICE PROVIDERS
 
 
 
 
 
 
 
15.6.1
INCREASING OUTSOURCING OF SPECIALIZED AI-ENABLED DISCOVERY ACTIVITIES DRIVES GROWTH
 
 
 
 
16
AI IN DRUG DISCOVERY MARKET, BY REGION
Comprehensive coverage of 8 Regions with country-level deep-dive of 17 Countries | 500 Data Tables.
 
 
 
 
 
237
 
16.1
INTRODUCTION
 
 
 
 
 
 
16.2
NORTH AMERICA
 
 
 
 
 
 
 
16.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
 
 
 
 
 
 
16.2.2
US
 
 
 
 
 
 
 
 
STRONG PHARMA–AI ECOSYSTEM AND HIGH R&D INVESTMENT
 
 
 
 
 
16.2.3
CANADA
 
 
 
 
 
 
 
 
STRONG AI RESEARCH BASE AND GROWING BIOPHARMA INNOVATION
 
 
 
 
16.3
EUROPE
 
 
 
 
 
 
 
16.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
 
 
 
 
 
 
16.3.2
GERMANY
 
 
 
 
 
 
 
 
AVAILABILITY OF ADVANCED COMPUTING AND RESEARCH INFRASTRUCTURE
 
 
 
 
 
16.3.3
UK
 
 
 
 
 
 
 
16.3.3.1
INCREASING INVESTMENT IN AI-BASED MOLECULAR DESIGN DRIVES DEMAND
 
 
 
 
 
16.3.4
SWITZERLAND
 
 
 
 
 
 
 
16.3.4.1
STRONG PHARMACEUTICAL AND BIOTECHNOLOGY ECOSYSTEM TO BOOST MARKET
 
 
 
 
 
16.3.5
FRANCE
 
 
 
 
 
 
 
16.3.5.1
LARGE-SCALE AI INVESTMENT BY PHARMACEUTICAL COMPANIES – KEY DRIVER
 
 
 
 
 
16.3.6
ITALY
 
 
 
 
 
 
 
 
MARKET DRIVEN BY COUNTRY’S STRONG PHARMACEUTICAL AND LIFE
 
 
 
 
 
16.3.7
SPAIN
 
 
 
 
 
 
 
16.3.7.1
EXPANSION OF AI-ENABLED BIOTECHNOLOGY RESEARCH DRIVES DEMAND
 
 
 
 
 
16.3.8
REST OF EUROPE
 
 
 
 
 
 
 
 
GROWING PHARMACEUTICAL R&D AND PUBLIC-SECTOR AI ADOPTION TO
 
 
 
 
16.4
ASIA PACIFIC
 
 
 
 
 
 
 
16.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
 
 
 
 
 
 
16.4.2
JAPAN
 
 
 
 
 
 
 
 
INCREASING PHARMACEUTICAL INVESTMENT IN AI AND ROBOTICS
 
 
 
 
 
16.4.3
CHINA
 
 
 
 
 
 
 
16.4.3.1
GROWTH OF AI-NATIVE BIOTECH COMPANIES BOOSTS DEMAND
 
 
 
 
 
16.4.4
INDIA
 
 
 
 
 
 
 
16.4.4.1
LARGE PHARMACEUTICAL AND BIOTECHNOLOGY ECOSYSTEM TO PROPEL MARKET
 
 
 
 
 
16.4.5
SOUTH KOREA
 
 
 
 
 
 
 
16.4.5.1
GOVERNMENT SUPPORT FOR AI-BASED DRUG DISCOVERY TO BOOST MARKET
 
 
 
 
 
16.4.6
AUSTRALIA
 
 
 
 
 
 
 
 
MARKET DRIVEN BY STRONG GOVERNMENT SUPPORT FOR AI AND
 
 
 
 
 
16.4.7
REST OF ASIA PACIFIC
 
 
 
 
 
 
 
16.4.7.1
GROWTH OF REGIONAL PHARMACEUTICAL AND BIOTECHNOLOGY CAPABILITIES TO BOOST MARKET
 
 
 
 
16.5
LATIN AMERICA
 
 
 
 
 
 
 
16.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
 
 
 
 
 
 
16.5.2
BRAZIL
 
 
 
 
 
 
 
16.5.2.1
EXPANDING PHARMACEUTICAL R&D AND EMERGING AI-BIOTECH ECOSYSTEM ACT AS MAJOR DRIVERS
 
 
 
 
 
16.5.3
MEXICO
 
 
 
 
 
 
 
16.5.3.1
MULTINATIONAL PHARMACEUTICAL ACTIVITY AND GOVERNMENT-BACKED RESEARCH TO DRIVE MARKET
 
 
 
 
 
16.5.4
REST OF LATIN AMERICA
 
 
 
 
 
 
 
16.5.4.1
GROWING RESEARCH BASE FOR AI TO DRIVE MARKET
 
 
 
 
16.6
MIDDLE EAST & AFRICA
 
 
 
 
 
 
 
16.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
 
 
 
 
 
 
16.6.2
GCC COUNTRIES
 
 
 
 
 
 
 
16.6.2.1
NATIONAL AI STRATEGIES AND GROWING TECHNOLOGY PARTNERSHIPS ACT AS MAJOR DRIVERS
 
 
 
 
 
16.6.3
SAUDI ARABIA
 
 
 
 
 
 
 
16.6.3.1
GOVERNMENT INVESTMENT IN BIOTECHNOLOGY AND LIFE SCIENCES PROPELS MARKET
 
 
 
 
 
16.6.4
UAE
 
 
 
 
 
 
 
16.6.4.1
GOVERNMENT-LED AI AND BIOTECHNOLOGY INVESTMENT BOOSTS MARKET
 
 
 
 
 
16.6.5
REST OF GCC
 
 
 
 
 
 
 
16.6.5.1
INTERNATIONAL AI-DRUG DISCOVERY PARTNERSHIPS DRIVE DEMAND
 
 
 
 
 
16.6.6
SOUTH AFRICA
 
 
 
 
 
 
 
16.6.6.1
STRONG DOMESTIC DRUG-DISCOVERY RESEARCH BASE DRIVES MARKET
 
 
 
 
 
16.6.7
REST OF MIDDLE EAST & AFRICA
 
 
 
 
 
 
 
16.6.7.1
EXPANSION OF LOCAL PHARMACEUTICAL AND BIOMANUFACTURING CAPABILITIES DRIVES DEMAND
 
 
 
17
COMPETITIVE LANDSCAPE
Gain insights into top AI drug discovery players' strategies, revenue, and market positioning.
 
 
 
 
 
484
 
17.1
OVERVIEW
 
 
 
 
 
 
17.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
 
 
 
 
 
 
 
17.2.1
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN DRUG DISCOVERY MARKET
 
 
 
 
 
17.3
REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
 
 
 
 
 
 
17.4
MARKET SHARE ANALYSIS, 2025
 
 
 
 
 
 
 
17.5
BRAND COMPARISON
 
 
 
 
 
 
 
17.6
VALUATION & FINANCIAL METRICS
 
 
 
 
 
 
 
17.6.1
FINANCIAL METRICS
 
 
 
 
 
 
17.6.2
COMPANY VALUATION
 
 
 
 
 
17.7
COMPANY EVALUATION MATRIX
 
 
 
 
 
 
 
 
17.7.1
STARS
 
 
 
 
 
 
17.7.2
EMERGING LEADERS
 
 
 
 
 
 
17.7.3
PERVASIVE PLAYERS
 
 
 
 
 
 
17.7.4
PARTICIPANTS
 
 
 
 
 
 
17.7.5
COMPANY FOOTPRINT: KEY PLAYERS, 2025
 
 
 
 
 
 
 
17.7.5.1
COMPANY FOOTPRINT
 
 
 
 
 
 
17.7.5.2
REGION FOOTPRINT
 
 
 
 
17.8
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
 
 
 
 
 
 
 
 
17.8.1
PROGRESSIVE COMPANIES
 
 
 
 
 
 
17.8.2
RESPONSIVE COMPANIES
 
 
 
 
 
 
17.8.3
DYNAMIC COMPANIES
 
 
 
 
 
 
17.8.4
STARTING BLOCKS
 
 
 
 
 
 
17.8.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
 
 
 
 
 
 
 
17.8.5.1
DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
17.8.5.2
COMPETITIVE BENCHMARKING OF STARTUPS/SMES
 
 
 
 
17.9
COMPETITIVE SCENARIO
 
 
 
 
 
 
 
17.9.1
PRODUCT/SERVICE LAUNCHES
 
 
 
 
 
 
17.9.2
DEALS
 
 
 
 
 
 
17.9.3
EXPANSIONS
 
 
 
 
 
 
17.9.4
OTHER DEVELOPMENTS
 
 
 
 
18
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
 
 
 
 
 
508
 
18.1
KEY PLAYERS
 
 
 
 
 
 
 
18.1.1
NVIDIA CORPORATION
 
 
 
 
 
 
 
18.1.1.1
BUSINESS OVERVIEW
 
 
 
 
 
 
18.1.1.2
PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
18.1.1.3
RECENT DEVELOPMENTS
 
 
 
 
 
 
 
 
18.1.1.3.1
PRODUCT/SERVICE LAUNCHES & APPROVALS
 
 
 
 
 
 
18.1.1.3.2
DEALS
 
 
 
 
 
 
18.1.1.3.3
OTHER DEVELOPMENTS
 
 
 
 
18.1.1.4
MNM VIEW
 
 
 
 
 
 
 
 
18.1.1.4.1
RIGHT TO WIN
 
 
 
 
 
 
18.1.1.4.2
STRATEGIC CHOICES
 
 
 
 
 
 
18.1.1.4.3
WEAKNESSES & COMPETITIVE THREATS
 
 
 
18.1.2
ALPHABET INC.
 
 
 
 
 
 
18.1.3
RECURSION
 
 
 
 
 
 
18.1.4
INSILICO MEDICINE
 
 
 
 
 
 
18.1.5
SCHRÖDINGER, INC.
 
 
 
 
 
 
18.1.6
BENEVOLENTAI
 
 
 
 
 
 
18.1.7
MICROSOFT CORPORATION
 
 
 
 
 
 
18.1.8
NUMERION LABS
 
 
 
 
 
 
18.1.9
ILLUMINA, INC.
 
 
 
 
 
 
18.1.10
XTALPI INC.
 
 
 
 
 
 
18.1.11
IKTOS
 
 
 
 
 
 
18.1.12
TEMPUS AI, INC.
 
 
 
 
 
 
18.1.13
DEEP GENOMICS, INC.
 
 
 
 
 
 
18.1.14
VERGE LABS
 
 
 
 
 
 
18.1.15
BENCHSCI
 
 
 
 
 
 
18.1.16
INSITRO
 
 
 
 
 
 
18.1.17
VALO HEALTH
 
 
 
 
 
 
18.1.18
BPGBIO, INC.
 
 
 
 
 
 
18.1.19
GENERATE:BIOMEDICINES
 
 
 
 
 
 
18.1.20
CERTARA, INC.
 
 
 
 
 
18.2
OTHER EMERGING PLAYERS
 
 
 
 
 
 
 
18.2.1
XAIRA THERAPEUTICS
 
 
 
 
 
 
18.2.2
IAMBIC THERAPEUTICS, INC.
 
 
 
 
 
 
18.2.3
GENESIS MOLECULAR AI
 
 
 
 
 
 
18.2.4
CRADLE BIO
 
 
 
 
 
 
18.2.5
ISOMORPHIC LABS
 
 
 
 
19
RESEARCH METHODOLOGY
 
 
 
 
 
599
 
19.1
RESEARCH APPROACH
 
 
 
 
 
 
 
19.1.1
SECONDARY RESEARCH
 
 
 
 
 
 
 
19.1.1.1
KEY DATA FROM SECONDARY SOURCES
 
 
 
 
 
19.1.2
PRIMARY RESEARCH
 
 
 
 
 
 
 
19.1.2.1
PRIMARY SOURCES
 
 
 
 
 
 
19.1.2.2
KEY DATA FROM PRIMARY SOURCES
 
 
 
 
 
 
19.1.2.3
BREAKDOWN OF PRIMARIES
 
 
 
 
 
 
19.1.2.4
INSIGHTS FROM PRIMARY EXPERTS
 
 
 
 
19.2
RESEARCH METHODOLOGY DESIGN
 
 
 
 
 
 
19.3
MARKET SIZE ESTIMATION
 
 
 
 
 
 
19.4
MARKET BREAKDOWN DATA TRIANGULATION
 
 
 
 
 
 
19.5
MARKET SHARE ESTIMATION
 
 
 
 
 
 
19.6
STUDY ASSUMPTIONS
 
 
 
 
 
 
19.7
RESEARCH LIMITATIONS
 
 
 
 
 
 
 
19.7.1
METHODOLOGY-RELATED LIMITATIONS
 
 
 
 
 
19.8
RISK ASSESSMENT
 
 
 
 
 
20
APPENDIX
 
 
 
 
 
615
 
20.1
DISCUSSION GUIDE
 
 
 
 
 
 
20.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
 
 
20.3
CUSTOMIZATION OPTIONS
 
 
 
 
 
 
20.4
RELATED REPORTS
 
 
 
 
 
 
20.5
AUTHOR DETAILS
 
 
 
 
 
LIST OF TABLES
 
 
 
 
 
 
 
TABLE 1
USD EXCHANGE RATES
 
 
 
 
 
 
TABLE 2
AI IN DRUG DISCOVERY: COLLABORATIONS AND PARTNERSHIPS, 2024–2026
 
 
 
 
 
 
TABLE 3
INDICATIVE LIST OF DRUGS LOSING PATENTS IN 2025 AND 2026
 
 
 
 
 
 
TABLE 4
AI IN DRUG DISCOVERY MARKET: ROLE IN ECOSYSTEM
 
 
 
 
 
 
TABLE 5
INDICATIVE PRICE FOR AI IN DRUG DISCOVERY PLATFORMS, BY KEY PLAYERS, 2025
 
 
 
 
 
 
TABLE 6
INDICATIVE PRICE FOR AI IN DRUG DISCOVERY MARKET, BY REGION (2025)
 
 
 
 
 
 
TABLE 7
KEY CONFERENCES & EVENTS IN AI IN DRUG DISCOVERY MARKET, JULY 2026-JUNE 2027
 
 
 
 
 
 
TABLE 8
CASE 1: TERRAY THERAPEUTICS’ USE OF NVIDIA TO ACCELERATE GENERATIVE AI-ENABLED SMALL-MOLECULE DRUG DISCOVERY
 
 
 
 
 
 
TABLE 9
CASE 2: ASTELLAS PHARMA’S USE OF NVIDIA AI TO ACCELERATE BIOMOLECULAR DISCOVERY AND COMPOUND SCREENING
 
 
 
 
 
 
TABLE 10
CASE 3: AMGEN–NVIDIA COLLABORATION ACCELERATES BIOLOGICS DISCOVERY THROUGH GENERATIVE AI
 
 
 
 
 
 
TABLE 11
US ADJUSTED RECIPROCAL TARIFF RATES
 
 
 
 
 
 
TABLE 12
JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR AI IN DRUG DISCOVERY
 
 
 
 
 
 
TABLE 13
AI IN DRUG DISCOVERY MARKET: KEY PATENTS/PATENT APPLICATIONS
 
 
 
 
 
 
TABLE 14
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 15
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 16
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 17
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 18
MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 19
REGULATORY SCENARIO OF NORTH AMERICA
 
 
 
 
 
 
TABLE 20
REGULATORY SCENARIO OF EUROPE
 
 
 
 
 
 
TABLE 21
REGULATORY SCENARIO OF ASIA PACIFIC
 
 
 
 
 
 
TABLE 22
REGULATORY SCENARIO OF LATIN AMERICA
 
 
 
 
 
 
TABLE 23
REGULATORY SCENARIO OF MIDDLE EAST & AFRICA
 
 
 
 
 
 
TABLE 24
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%)
 
 
 
 
 
 
TABLE 25
KEY BUYING CRITERIA FOR TOP THREE END USERS
 
 
 
 
 
 
TABLE 26
AI IN DRUG DISCOVERY MARKET: UNMET NEEDS
 
 
 
 
 
 
TABLE 27
DRUG DISCOVERY MARKET: END USER EXPECTATIONS
 
 
 
 
 
 
TABLE 28
AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 29
AI IN DRUG DISCOVERY MARKET FOR TARGET IDENTIFICATION & SELECTION, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 30
AI IN DRUG DISCOVERY MARKET FOR TARGET VALIDATION, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 31
AI IN DRUG DISCOVERY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 32
AI IN DRUG DISCOVERY MARKET FOR HIT TO LEAD IDENTIFICATION/LEAD GENERATION, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 33
AI IN DRUG DISCOVERY MARKET FOR LEAD OPTIMIZATION, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 34
AI IN DRUG DISCOVERY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 35
AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 36
MACHINE LEARNING: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 37
MACHINE LEARNING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 38
DEEP LEARNING: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 39
DEEP LEARNING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 40
TRANSFORMER-BASED ARCHITECTURE: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 41
GRAPH NEURAL NETWORKS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 42
CONVOLUTIONAL NEURAL NETWORKS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 43
DIFFUSION AND FLOW-BASED MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 44
GAN & VAE: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 45
RECURRENT & SEQUENCE MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 46
OTHER DEEP LEARNING TECHNOLOGIES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 47
SUPERVISED LEARNING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 48
SELF-SUPERVISED & REPRESENTATION LEARNING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 49
REINFORCEMENT LEARNING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 50
UNSUPERVISED LEARNING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 51
OTHER MACHINE LEARNING TECHNOLOGIES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 52
GENERATIVE AI: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 53
GENERATIVE AI: AI IN DRUG DISCOVERY, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 54
MOLECULAR GENERATIVE MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 55
PROTEIN & BIOLOGICS GENERATIVE MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 56
LARGE LANGUAGE MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 57
FOUNDATION MODELS: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 58
FOUNDATION MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 59
CHEMISTRY FOUNDATION MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 60
PROTEIN LANGUAGE MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 61
BIOLOGY AND MULTIOMICS FOUNDATION MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 62
AGENTIC AI & CO-SCIENTISTS: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 63
AGENTIC AI & CO-SCIENTISTS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 64
AUTONOMOUS RESEARCH AGENTS & WORKFLOW ORCHESTRATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 65
MULTI-AGENT REASONING SYSTEMS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 66
LAB-IN-THE-LOOP & CLOSED-LOOP EXPERIMENTATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 67
KNOWLEDGE GRAPHS AND SEMANTIC REASONING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 68
NATURAL LANGUAGE PROCESSING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 69
COMPUTER VISION & IMAGE ANALYSIS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 70
PHYSICS-BASED & HYBRID AI MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 71
AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 72
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 73
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 74
LARGE PHARMACEUTICAL COMPANIES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 75
SMALL & MID-SIZED BIOTECHNOLOGY COMPANIES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 76
CROS & CDMOS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 77
RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 78
AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 79
UNDERSTANDING DISEASE BIOLOGY: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 80
UNDERSTANDING DISEASE BIOLOGY: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 81
EVIDENCE SYNTHESIS AND SCIENTIFIC LITERATURE INTELLIGENCE: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 82
MULTIOMICS INTEGRATION & TARGET DISEASE ASSOCIATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 83
EXPERIMENT DESIGN & REAGENT/MODEL SELECTION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 84
PROTEIN STRUCTURE & INTERACTION PREDICTION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 85
DRUG REPURPOSING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 86
DE NOVO DRUG DESIGN: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 87
DE NOVO DRUG DESIGN: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 88
SMALL MOLECULE DESIGN: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 89
VACCINE DESIGN: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 90
ANTIBODY & OTHER BIOLOGICS DESIGN: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 91
PROTEIN & ENZYME DESIGN: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 92
DRUG OPTIMIZATION: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 93
DRUG OPTIMIZATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 94
SMALL MOLECULE OPTIMIZATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 95
VACCINE OPTIMIZATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 96
ANTIBODY & OTHER BIOLOGICS OPTIMIZATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 97
SAFETY & TOXICITY: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 98
AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 99
ON-PREMISE SOLUTIONS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 100
CLOUD-BASED SOLUTIONS: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 101
CLOUD-BASED SOLUTIONS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 102
PUBLIC DEPLOYMENT: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 103
PRIVATE CLOUD/VPC/SOVEREIGN DEPLOYMENT: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 104
HYBRID SOLUTIONS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 105
AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 106
ONCOLOGY: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 107
INFECTIOUS DISEASES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 108
NEUROLOGY: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 109
CARDIOVASCULAR DISEASES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 110
METABOLIC DISEASES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 111
IMMUNOLOGY: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 112
RARE & GENETIC DISORDERS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 113
MENTAL DISORDERS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 114
OTHER THERAPEUTIC AREAS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 115
AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 116
END-TO-END SOLUTION PROVIDERS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 117
NICHE/POINT SOLUTION PROVIDERS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 118
AI TECHNOLOGY PROVIDERS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 119
COMPUTE & INFRASTRUCTURE PROVIDERS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 120
BUSINESS PROCESS SERVICE PROVIDERS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 121
AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 122
NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 123
NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 124
NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 125
NORTH AMERICA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 126
NORTH AMERICA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 127
NORTH AMERICA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 128
NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 129
NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 130
NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 131
NORTH AMERICA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 132
NORTH AMERICA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 133
NORTH AMERICA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 134
NORTH AMERICA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 135
NORTH AMERICA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 136
NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 137
NORTH AMERICA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 138
NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 139
NORTH AMERICA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 140
US: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 141
US: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 142
US: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 143
US: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 144
US: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 145
US: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 146
US: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 147
US: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 148
US: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 149
US: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 150
US: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 151
US: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 152
US: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 153
US: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 154
US: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 155
US: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 156
US: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 157
CANADA: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 158
CANADA: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 159
CANADA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 160
CANADA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 161
CANADA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 162
CANADA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 163
CANADA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 164
CANADA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 165
CANADA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 166
CANADA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 167
CANADA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 168
CANADA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 169
CANADA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 170
CANADA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 171
CANADA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 172
CANADA: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 173
CANADA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 174
EUROPE: AI IN DRUG DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 175
EUROPE: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 176
EUROPE: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 177
EUROPE: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 178
EUROPE: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 179
EUROPE: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 180
EUROPE: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 181
EUROPE: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 182
EUROPE: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 183
EUROPE: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 184
EUROPE: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 185
EUROPE: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 186
EUROPE: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 187
EUROPE: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 188
EUROPE: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 189
EUROPE: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 190
EUROPE: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 191
EUROPE: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 192
GERMANY: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 193
GERMANY: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 194
GERMANY: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 195
GERMANY: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 196
GERMANY: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 197
GERMANY: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 198
GERMANY: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 199
GERMANY: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 200
GERMANY: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 201
GERMANY: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 202
GERMANY: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 203
GERMANY: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 204
GERMANY: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 205
GERMANY: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 206
GERMANY: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 207
GERMANY: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 208
GERMANY: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 209
UK: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 210
UK: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 211
UK: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 212
UK: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 213
UK: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 214
UK: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 215
UK: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 216
UK: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 217
UK: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 218
UK: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 219
UK: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 220
UK: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 221
UK: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 222
UK: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 223
UK: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 224
UK: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 225
UK: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 226
SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 227
SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 228
SWITZERLAND: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 229
SWITZERLAND: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 230
SWITZERLAND: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 231
SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 232
SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 233
SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 234
SWITZERLAND: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 235
SWITZERLAND: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 236
SWITZERLAND: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 237
SWITZERLAND: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 238
SWITZERLAND: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 239
SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 240
SWITZERLAND: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 241
SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 242
SWITZERLAND: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 243
FRANCE: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 244
FRANCE: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 245
FRANCE: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 246
FRANCE: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 247
FRANCE: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 248
FRANCE: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 249
FRANCE: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 250
FRANCE: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 251
FRANCE: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 252
FRANCE: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 253
FRANCE: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 254
FRANCE: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 255
FRANCE: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 256
FRANCE: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 257
FRANCE: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 258
FRANCE: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 259
FRANCE: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 260
ITALY: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 261
ITALY: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 262
ITALY: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 263
ITALY: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 264
ITALY: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 265
ITALY: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 266
ITALY: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 267
ITALY: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 268
ITALY: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 269
ITALY: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 270
ITALY: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 271
ITALY: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 272
ITALY: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 273
ITALY: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 274
ITALY: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 275
ITALY: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 276
ITALY: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 277
SPAIN: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 278
SPAIN: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 279
SPAIN: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 280
SPAIN: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 281
SPAIN: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 282
SPAIN: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 283
SPAIN: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 284
SPAIN: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 285
SPAIN: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 286
SPAIN: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 287
SPAIN: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 288
SPAIN: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 289
SPAIN: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 290
SPAIN: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 291
SPAIN: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 292
SPAIN: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 293
SPAIN: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 294
REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 295
REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 296
REST OF EUROPE: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 297
REST OF EUROPE: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 298
REST OF EUROPE: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 299
REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 300
REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 301
REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 302
REST OF EUROPE: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 303
REST OF EUROPE: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 304
REST OF EUROPE: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 305
REST OF EUROPE: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 306
REST OF EUROPE: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 307
REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 308
REST OF EUROPE: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 309
REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 310
REST OF EUROPE: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 311
ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 312
ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 313
ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 314
ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 315
ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 316
ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 317
ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 318
ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 319
ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 320
ASIA PACIFIC: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 321
ASIA PACIFIC: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 322
ASIA PACIFIC: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 323
ASIA PACIFIC: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 324
ASIA PACIFIC: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 325
ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 326
ASIA PACIFIC: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 327
ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 328
ASIA PACIFIC: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 329
JAPAN: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 330
JAPAN: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 331
JAPAN: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 332
JAPAN: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 333
JAPAN: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 334
JAPAN: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 335
JAPAN: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 336
JAPAN: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 337
JAPAN: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 338
JAPAN: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 339
JAPAN: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 340
JAPAN: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 341
JAPAN: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 342
JAPAN: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 343
JAPAN: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 344
JAPAN: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 345
JAPAN: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 346
CHINA: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 347
CHINA: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 348
CHINA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 349
CHINA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 350
CHINA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 351
CHINA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 352
CHINA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 353
CHINA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 354
CHINA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 355
CHINA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 356
CHINA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 357
CHINA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 358
CHINA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 359
CHINA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 360
CHINA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 361
CHINA: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 362
CHINA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 363
INDIA: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 364
INDIA: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 365
INDIA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 366
INDIA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 367
INDIA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 368
INDIA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 369
INDIA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 370
INDIA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 371
INDIA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 372
INDIA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 373
INDIA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 374
INDIA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 375
INDIA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 376
INDIA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 377
INDIA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 378
INDIA: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 379
INDIA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 380
SOUTH KOREA: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 381
SOUTH KOREA: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 382
SOUTH KOREA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 383
SOUTH KOREA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 384
SOUTH KOREA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 385
SOUTH KOREA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 386
SOUTH KOREA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 387
SOUTH KOREA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 388
SOUTH KOREA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 389
SOUTH KOREA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 390
SOUTH KOREA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 391
SOUTH KOREA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 392
SOUTH KOREA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 393
SOUTH KOREA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 394
SOUTH KOREA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 395
SOUTH KOREA: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 396
SOUTH KOREA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 397
AUSTRALIA: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 398
AUSTRALIA: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 399
AUSTRALIA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 400
AUSTRALIA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 401
AUSTRALIA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 402
AUSTRALIA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 403
AUSTRALIA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 404
AUSTRALIA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 405
AUSTRALIA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 406
AUSTRALIA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 407
AUSTRALIA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 408
AUSTRALIA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 409
AUSTRALIA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 410
AUSTRALIA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 411
AUSTRALIA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 412
AUSTRALIA: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 413
AUSTRALIA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 414
REST OF ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 415
REST OF ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 416
REST OF ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 417
REST OF ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 418
REST OF ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 419
REST OF ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 420
REST OF ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 421
REST OF ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 422
REST OF ASIA PACIFIC: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 423
REST OF ASIA PACIFIC: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 424
REST OF ASIA PACIFIC: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 425
REST OF ASIA PACIFIC: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 426
REST OF ASIA PACIFIC: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 427
REST OF ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 428
REST OF ASIA PACIFIC: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 429
REST OF ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 430
REST OF ASIA PACIFIC: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 431
LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 432
LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 433
LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 434
LATIN AMERICA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 435
LATIN AMERICA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 436
LATIN AMERICA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 437
LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 438
LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 439
LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 440
LATIN AMERICA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 441
LATIN AMERICA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 442
LATIN AMERICA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 443
LATIN AMERICA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 444
LATIN AMERICA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 445
LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 446
LATIN AMERICA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 447
LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 448
LATIN AMERICA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 449
BRAZIL: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 450
BRAZIL: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 451
BRAZIL: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 452
BRAZIL: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 453
BRAZIL: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 454
BRAZIL: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 455
BRAZIL: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 456
BRAZIL: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 457
BRAZIL: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 458
BRAZIL: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 459
BRAZIL: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 460
BRAZIL: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 461
BRAZIL: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 462
BRAZIL: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 463
BRAZIL: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 464
BRAZIL: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 465
BRAZIL: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 466
MEXICO: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 467
MEXICO: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 468
MEXICO: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 469
MEXICO: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 470
MEXICO: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 471
MEXICO: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 472
MEXICO: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 473
MEXICO: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 474
MEXICO: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 475
MEXICO: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 476
MEXICO: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 477
MEXICO: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 478
MEXICO: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 479
MEXICO: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 480
MEXICO: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 481
MEXICO: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 482
MEXICO: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 483
REST OF LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 484
REST OF LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 485
REST OF LATIN AMERICA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 486
REST OF LATIN AMERICA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 487
REST OF LATIN AMERICA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 488
REST OF LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 489
REST OF LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 490
REST OF LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 491
REST OF LATIN AMERICA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 492
REST OF LATIN AMERICA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 493
REST OF LATIN AMERICA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 494
REST OF LATIN AMERICA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 495
REST OF LATIN AMERICA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 496
REST OF LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 497
REST OF LATIN AMERICA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 498
REST OF LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 499
REST OF LATIN AMERICA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 500
MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 501
MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 502
MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 503
MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 504
MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 505
MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 506
MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 507
MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 508
MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 509
MIDDLE EAST & AFRICA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 510
MIDDLE EAST & AFRICA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 511
MIDDLE EAST & AFRICA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 512
MIDDLE EAST & AFRICA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 513
MIDDLE EAST & AFRICA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 514
MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 515
MIDDLE EAST & AFRICA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 516
MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 517
MIDDLE EAST & AFRICA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 518
GCC COUNTRIES: AI IN DRUG DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 519
GCC COUNTRIES: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 520
GCC COUNTRIES: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 521
GCC COUNTRIES: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 522
GCC COUNTRIES: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 523
GCC COUNTRIES: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 524
GCC COUNTRIES: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 525
GCC COUNTRIES: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 526
GCC COUNTRIES: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 527
GCC COUNTRIES: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 528
GCC COUNTRIES: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 529
GCC COUNTRIES: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 530
GCC COUNTRIES: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 531
GCC COUNTRIES: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 532
GCC COUNTRIES: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 533
GCC COUNTRIES: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 534
GCC COUNTRIES: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 535
GCC COUNTRIES: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 536
SAUDI ARABIA: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 537
SAUDI ARABIA: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 538
SAUDI ARABIA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 539
SAUDI ARABIA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 540
SAUDI ARABIA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 541
SAUDI ARABIA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 542
SAUDI ARABIA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 543
SAUDI ARABIA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 544
SAUDI ARABIA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 545
SAUDI ARABIA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 546
SAUDI ARABIA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 547
SAUDI ARABIA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 548
SAUDI ARABIA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 549
SAUDI ARABIA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 550
SAUDI ARABIA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 551
SAUDI ARABIA: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 552
SAUDI ARABIA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 553
UAE: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 554
UAE: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 555
UAE: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 556
UAE: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 557
UAE: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 558
UAE: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 559
UAE: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 560
UAE: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 561
UAE: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 562
UAE: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 563
UAE: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 564
UAE: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 565
UAE: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 566
UAE: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 567
UAE: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 568
UAE: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 569
UAE: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 570
REST OF GCC: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 571
REST OF GCC: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 572
REST OF GCC: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 573
REST OF GCC: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 574
REST OF GCC: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 575
REST OF GCC: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 576
REST OF GCC: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 577
REST OF GCC: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 578
REST OF GCC: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 579
REST OF GCC: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 580
REST OF GCC: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 581
REST OF GCC: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 582
REST OF GCC: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 583
REST OF GCC: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 584
REST OF GCC: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 585
REST OF GCC: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 586
REST OF GCC: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 587
SOUTH AFRICA: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 588
SOUTH AFRICA: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 589
SOUTH AFRICA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 590
SOUTH AFRICA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 591
SOUTH AFRICA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 592
SOUTH AFRICA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 593
SOUTH AFRICA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 594
SOUTH AFRICA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 595
SOUTH AFRICA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 596
SOUTH AFRICA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 597
SOUTH AFRICA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 598
SOUTH AFRICA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 599
SOUTH AFRICA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 600
SOUTH AFRICA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 601
SOUTH AFRICA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 602
SOUTH AFRICA: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 603
SOUTH AFRICA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 604
REST OF MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 605
REST OF MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 606
REST OF MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 607
REST OF MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 608
REST OF MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 609
REST OF MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 610
REST OF MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 611
REST OF MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 612
REST OF MIDDLE EAST & AFRICA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 613
REST OF MIDDLE EAST & AFRICA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 614
REST OF MIDDLE EAST & AFRICA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 615
REST OF MIDDLE EAST & AFRICA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 616
REST OF MIDDLE EAST & AFRICA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 617
REST OF MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 618
REST OF MIDDLE EAST & AFRICA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 619
REST OF MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 620
REST OF MIDDLE EAST & AFRICA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 621
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN DRUG DISCOVERY MARKET, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 622
AI IN DRUG DISCOVERY MARKET: DEGREE OF COMPETITION
 
 
 
 
 
 
TABLE 623
AI IN DRUG DISCOVERY MARKET: REGION FOOTPRINT
 
 
 
 
 
 
TABLE 624
AI IN DRUG DISCOVERY MARKET: USE CASE FOOTPRINT
 
 
 
 
 
 
TABLE 625
AI IN DRUG DISCOVERY MARKET: PROCESS FOOTPRINT
 
 
 
 
 
 
TABLE 626
AI IN DRUG DISCOVERY MARKET: THERAPEUTIC AREA FOOTPRINT
 
 
 
 
 
 
TABLE 627
AI IN DRUG DISCOVERY MARKET: PLAYER TYPE FOOTPRINT
 
 
 
 
 
 
TABLE 628
AI IN DRUG DISCOVERY MARKET: DEPLOYMENT FOOTPRINT
 
 
 
 
 
 
TABLE 629
AI IN DRUG DISCOVERY MARKET: DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
TABLE 630
AI IN DRUG DISCOVERY MARKET: REGION FOOTPRINT (STARTUPS/SMES)
 
 
 
 
 
 
TABLE 631
AI IN DRUG DISCOVERY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY PROCESS
 
 
 
 
 
 
TABLE 632
AI IN DRUG DISCOVERY MARKET: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 633
AI IN DRUG DISCOVERY MARKET: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 634
AI IN DRUG DISCOVERY MARKET: EXPANSIONS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 635
AI IN DRUG DISCOVERY MARKET: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 636
NVIDIA CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 637
NVIDIA CORPORATION: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 638
NVIDIA CORPORATION: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 639
NVIDIA CORPORATION: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 640
NVIDIA: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 641
ALPHABET INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 642
ALPHABET, INC: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 643
ALPHABET INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 644
ALPHABET INC.: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 645
ALPHABET, INC.: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 646
RECURSION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 647
RECURSION: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 648
RECURSION: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 649
RECURSION: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 650
RECURSION: EXPANSION, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 651
INSILICO MEDICINE: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 652
INSILICO MEDICINE: PRODUCTS /SERVICES OFFERED
 
 
 
 
 
 
TABLE 653
INSILICO MEDICINE: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 654
INSILICO MEDICINE: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 655
INSILICO MEDICINE: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 656
INSILICO MEDICINE: EXPANSIONS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 657
SCHRÖDINGER, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 658
SCHRÖDINGER, INC.: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 659
SCHRÖDINGER, INC.: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 660
SCHRÖDINGER, INC.: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 661
BENEVOLENTAI: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 662
BENEVOLENTAI: PRODUCTS/ SERVICES OFFERED
 
 
 
 
 
 
TABLE 663
BENEVOLENTAI: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 664
MICROSOFT CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 665
MICROSOFT CORPORATION: PRODUCTS /SERVICES OFFERED
 
 
 
 
 
 
TABLE 666
MICROSOFT CORPORATION: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 667
MICROSOFT CORPORATION: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 668
NUMERION LABS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 669
NUMERION LABS: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 670
ILLUMINA, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 671
ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 672
ILLUMINA, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 673
ILLUMINA, INC.: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 674
XTALPI INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 675
XTALPI INC.: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 676
XTALPI INC.: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 677
IKTOS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 678
IKTOS: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 679
IKTOS: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 680
IKTOS: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 681
TEMPUS AI, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 682
TEMPUS AI, INC.: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 683
TEMPUS AI, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 684
TEMPUS AI, INC.: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 685
DEEP GENOMICS, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 686
DEEP GENOMICS, INC.: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 687
DEEP GENOMICS, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 688
VERGE LABS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 689
VERGE LABS: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 690
VERGE GENOMICS: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 691
BENCHSCI: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 692
BENCHSCI: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 693
BENCHSCI: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 694
BENCHSCI: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 695
BENCHSCI: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 696
INSITRO: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 697
INSITRO: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 698
INSITRO: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 699
INSITRO: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 700
VALO HEALTH: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 701
VALO HEALTH: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 702
VALO HEALTH: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 703
VALO HEALTH: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 704
BPGBIO, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 705
BPGBIO, INC.: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 706
BPGBIO, INC.: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 707
GENERATE:BIOMEDICINES: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 708
GENERATE:BIOMEDICINES: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 709
GENERATE:BIOMEDICINES: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 710
GENERATE:BIOMEDICINES: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 711
GENERATE:BIOMEDICINES: EXPANSIONS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 712
CERTARA, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 713
CERTARA, INC.: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 714
CERTARA, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 715
CERTARA, INC.: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 716
RISK ASSESSMENT: AI IN DRUG DISCOVERY MARKET
 
 
 
 
 
 
LIST OF FIGURES
 
 
 
 
 
 
 
FIGURE 1
AI IN DRUG DISCOVERY MARKET SEGMENTATION
 
 
 
 
 
 
FIGURE 2
REGIONAL SCOPE
 
 
 
 
 
 
FIGURE 3
MARKET SCENARIO
 
 
 
 
 
 
FIGURE 4
GLOBAL AI IN DRUG DISCOVERY MARKET, 2024–2031
 
 
 
 
 
 
FIGURE 5
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN DRUG DISCOVERY MARKET, 2023–2026
 
 
 
 
 
 
FIGURE 6
DISRUPTIONS INFLUENCING GROWTH OF AI IN DRUG DISCOVERY MARKET
 
 
 
 
 
 
FIGURE 7
HIGH-GROWTH SEGMENTS IN AI IN DRUG DISCOVERY MARKET, 2026–2031
 
 
 
 
 
 
FIGURE 8
ASIA PACIFIC TO REGISTER HIGHEST CAGR IN AI IN DRUG DISCOVERY MARKET DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 9
RISING DEMAND FOR AI IN DRUG DISCOVERY AND REDUCED DRUG DEVELOPMENT COSTS TO DRIVE MARKET GROWTH
 
 
 
 
 
 
FIGURE 10
CLOUD-BASED SOLUTIONS AND US ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA IN 2025
 
 
 
 
 
 
FIGURE 11
JAPAN TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 12
DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN ENVIRONMENTAL MONITORING MARKET
 
 
 
 
 
 
FIGURE 13
APPROVAL OF PERSONALIZED MEDICINES BY US FDA, 2020–2024
 
 
 
 
 
 
FIGURE 14
AI IN DRUG DISCOVERY MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
FIGURE 15
AI IN DRUG DISCOVERY MARKET: VALUE CHAIN ANALYSIS
 
 
 
 
 
 
FIGURE 16
AI IN DRUG DISCOVERY MARKET: ECOSYSTEM ANALYSIS
 
 
 
 
 
 
FIGURE 17
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
 
 
 
 
 
 
FIGURE 19
PATENT PUBLICATION TRENDS IN AI IN DRUG DISCOVERY MARKET, 2015–2026
 
 
 
 
 
 
FIGURE 20
JURISDICTION AND TOP APPLICANT ANALYSIS FOR AI IN DRUG DISCOVERY MARKET
 
 
 
 
 
 
FIGURE 21
TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR AI IN DRUG DISCOVERY MARKET (JANUARY 2015 TO AUGUST 2026)
 
 
 
 
 
 
FIGURE 22
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
 
 
 
 
 
 
FIGURE 23
KEY BUYING CRITERIA FOR TOP THREE END USERS
 
 
 
 
 
 
FIGURE 24
NORTH AMERICA: AI IN DRUG DISCOVERY MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 25
ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 26
AI IN DRUG DISCOVERY MARKET: REVENUE ANALYSIS OF KEY PLAYERS
 
 
 
 
 
 
FIGURE 27
AI IN DRUG DISCOVERY MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025
 
 
 
 
 
 
FIGURE 28
AI IN DRUG DISCOVERY MARKET: BRAND COMPARATIVE ANALYSIS
 
 
 
 
 
 
FIGURE 29
EV/EBITDA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 30
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 31
AI IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX, KEY PLAYERS (2025)
 
 
 
 
 
 
FIGURE 32
AI IN DRUG DISCOVERY MARKET: COMPANY FOOTPRINT
 
 
 
 
 
 
FIGURE 33
AI IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
 
 
 
 
 
 
FIGURE 34
NVIDIA CORPORATION: COMPANY SNAPSHOT (2026)
 
 
 
 
 
 
FIGURE 35
ALPHABET INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 36
RECURSION: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 37
INSILICO MEDICINE: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 38
SCHRÖDINGER, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 39
MICROSOFT CORPORATION: COMPANY SNAPSHOT (2026)
 
 
 
 
 
 
FIGURE 40
ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 41
XTALPI INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 42
TEMPUS AI, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 43
CERTARA, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 44
RESEARCH DESIGN
 
 
 
 
 
 
FIGURE 45
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
 
 
 
 
 
 
FIGURE 46
RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
 
 
 
 
 
 
FIGURE 47
BOTTOM-UP APPROACH
 
 
 
 
 
 
FIGURE 48
TOP-DOWN APPROACH
 
 
 
 
 
 
FIGURE 49
CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF AI IN DRUG DISCOVERY INDUSTRY
 
 
 
 
 
 
FIGURE 50
CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
 
 
 
 
 
 
FIGURE 51
DATA TRIANGULATION METHODOLOGY
 
 
 
 
 
 

 

Methodology

The study involved significant activities in estimating the current size of the AI in drug discovery market. Exhaustive secondary research was done to collect information on the market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the AI in drug discovery market.

Secondary Research

This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and Companies House documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in drug discovery solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.

Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in drug discovery vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.

Primary Research

In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources are mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.

Primary research was conducted to identify segmentation types; industry trends; key players; and key market dynamics such as drivers, restraints, opportunities, challenges, industry trends, and strategies adopted by key players. After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at.

In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

Breakdown of the Primary Respondents:

AI in Drug Discovery Market Size, and Share

Note: Other designations include sales managers, marketing managers, and product managers.
Note: Tiers are defined based on a company’s total revenue as of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (revenue share analysis of leading players) and the top-down approach (assessment of utilization/adoption/penetration trends by offering, function, application, deployment, tools, end user, and region).

AI in Drug Discovery Market : Top-Down and Bottom-Up Approach

AI in Drug Discovery Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the AI in drug discovery market. 

Market Definition

The AI in drug discovery market comprises artificial intelligence-based software platforms and computational solutions that accelerate early-stage drug discovery by enabling target identification, lead optimization, candidate selection, and drug repurposing. These solutions leverage technologies such as machine learning, deep learning, and generative AI to improve R&D efficiency, reduce costs, and shorten drug development timelines.

Key Stakeholders

  • AI in drug discovery software vendors
  • AI in drug discovery service providers
  • Pharmaceutical companies
  • Biotechnology companies
  • AI technology providers
  • Drug discovery software providers
  • Contract Research Organizations (CROs)
  • Academic and research institutes
  • Clinical research organizations
  • Cloud service and high-performance computing (HPC) providers
  • Genomics and multi-omics data providers
  • Healthcare data and bioinformatics companies
  • Government agencies and regulatory authorities
  • Venture capital firms and strategic investors
  • Healthcare and life sciences consulting firms
  • Contract Development and Manufacturing Organizations (CDMOs)
  • Healthcare providers (involved in translational research)
  • Precision medicine and companion diagnostics companies
  • Life sciences distributors and technology integrators

Report Objectives

  • To describe and forecast the global AI in drug discovery market, by process, use case, therapeutic area, player type, AI tool, deployment model, end user, and region, in terms of value
  • To provide detailed information regarding the factors such as the drivers, restraints, opportunities, and challenges influencing the growth of the market
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall AI in drug discovery market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the AI in drug discovery market in five main regions (along with their respective key countries): North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa, in terms of value
  • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies in the market
  • To track and analyze competitive developments such as product & service launches, expansions, partnerships, agreements, collaborations, and acquisitions in the AI in drug discovery market
  • To benchmark players within the AI in drug discovery market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offering

Available customizations:

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

Geographic Analysis

  • Further breakdown of the Rest of Europe’s AI in drug discovery market into Denmark, Norway, and others

  • Further breakdown of the Rest of Asia Pacific AI in drug discovery market into Vietnam, New Zealand, Australia, South Korea, and others

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)

 

Key Questions Addressed by the Report

Which are the top industry players in the AI in drug discovery market?
The top market players in the global AI in drug discovery market include The artificial intelligence (AI) in drug discovery market is dominated by key players. The prominent players operating in this market are NVIDIA Corporation (US), Exscientia (UK), Google (US), BenevolentAI (UK), Recursion (US), Insilico Medicine (US), Schrödinger, Inc. (US), Microsoft (US), Atomwise Inc. (US), Illumina, Inc. (US), Valo Health (US), Merck KGaA (Germany), IQVIA (US), CytoReason (Israel) AbCellera (US), and others.
Which deployment models have been included in the AI in drug discovery market report?
This report contains the following components:
  • On-premise
  • Cloud-based
  • SaaS-based
Which geographical region dominates the global AI in drug discovery market?
The global AI in drug discovery market is further bifurcated into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America holds a substantial share, and registers the highest growth rate during the forecast period.
Which end users have been included in the AI in drug discovery market report?
The report contains the following industry segments:
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Research Centers, Academic Institutes, & Government Organizations
What is the total CAGR expected to be recorded for the AI in drug discovery market during 2024-2029?
The CAGR is expected to record a CAGR of 29.9% from 2024-2029.

 

Table of Contents

Methodology

 Request Customization Speak to Analyst
Speak to Analyst
Fact checked
Cite this Research

Adjacent Markets

Request Bundle Reports

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the AI in Drug Discovery Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

TESTIMONIALS

Growth opportunities and latent adjacency in AI in Drug Discovery Market

avtar

Anthony

Jun, 2022

Which market segment is expected to shape the future of the AI in Drug Discovery Market?.

avtar

Adam

Jun, 2022

Which are the most innovative companies in AI in Drug Discovery Market?.

avtar

Mathew

Jun, 2022

What are the new trends and advancements in the AI in Drug Discovery Market?.

DMCA.com Protection Status
popup img